Should you buy Moderna stock now?
The technical signal for Moderna is currently NEUTRAL. Moderna trades at $54.89 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -1.987 with falling momentum (signal: -1.305); RSI is at 43.8 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $50.84 is 7.4% below the current price. This is a technical observation based on current data, not investment advice.
What is the price target for Moderna stock?
The average analyst price target for Moderna is $50.84. The current price is $54.89, which gives a downside of 7.4%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $45.76 and $55.92.
Is Moderna a dividend stock?
No, Moderna does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Moderna stock?
Moderna is rated as a stock with high risk. the annual standard deviation is 68.7%, which classifies the stock as high risk.
Is Moderna overvalued?
Moderna is considered fairly valued – the price is close to the analyst price target. Moderna has the following valuation ratios: a P/S ratio of 10.2, a P/B ratio of 3.2. The stock trades close to the analyst price target and is considered fairly valued.
Is Moderna overbought?
No, Moderna is not overbought. RSI is at 43.8 (neutral zone). The technical indicators show: RSI is at 43.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 9.1% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Moderna earnings report?
The date of the next earnings report for Moderna has not been published yet. Check the company's investor calendar for updates.
Is Moderna shorted?
Yes, Moderna is shorted with 16.2% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Moderna stock?
No, insiders are not buying Moderna shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 17 sales. On a net basis, 9,018,076 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 10,037,588 $ sold. Active sellers include Hoge Stephen, Mock James M, Klinger Shannon Thyme and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Moderna a good stock?
Based on our total score, Moderna is rated as a poor stock with a total score of 21 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 16/100, Quality: 2/100, Momentum: 45/100. In addition: technical signal: Hold. Whether Moderna is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Moderna stock?
The outlook for Moderna based on current data: the average analyst price target is $50.84 (-7.4%). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Moderna stock falling?
Moderna is falling right now. The technical indicators show: the price is 9.1% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 16.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Moderna go?
The average analyst price target for Moderna is $50.84, which is 7.4% below the current price of $54.89. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Moderna fall?
We lack enough history to give a specific floor for Moderna. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Moderna do?
Moderna, Inc. er et biotekfirma, der udvikler og sælger medicin og vacciner baseret på mRNA-teknologi. De tjener penge på at behandle infektionssygdomme, kræft og sjældne lidelser. Deres mest kendte produkter er COVID-19-vaccinen, men de laver også vacciner mod influenza og cy... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Moderna as an investment.
Did Moderna raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Moderna. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Moderna making money or losing money?
No, Moderna is currently not making money — the company is losing money with a negative profit margin of -141.4%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Moderna go bankrupt?
The bankruptcy risk of Moderna is rated as low. Altman Z2 (a model for assessing financial distress) is 3.29 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 30% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Moderna have a lot of debt?
No, Moderna has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 30%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
